Table 3. The levels of four markers in different TMN stages.
| Biomarkers | Phase I (n=16) | Phase II (n=35) | Phase III (n=42) | Phase IV (n=27) |
|---|---|---|---|---|
| CEA (ng/mL) | 4.40±2.29 | 8.71±4.92# | 10.05±2.84#∆ | 13.62±3.03#∆▲ |
| CYFRA21-1 (ng/mL) | 6.64±2.11 | 8.70±2.95# | 9.16±2.54#∆ | 9.62±2.78 |
| SCC-Ag (ng/mL) | 3.46±1.72 | 2.98±1.13 | 3.08±1.03 | 3.14±1.28 |
| pro-GRP (pg/mL) | 51.06±20.87 | 65.06±23.72# | 76.38±24.36#∆ | 89.42±25.62#∆▲ |
#, P<0.05, compared with stage I; ∆, P<0.05, compared with stage II, ▲, P<0.05, compared with stage III. CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragment; SCC-Ag, squamous cell carcinoma antigen; pro-GRP, gastrin-releasing peptide.